Healthcare

● BSX closed at $42.71 on 9 October 2026, and the second data set's $59.72 average target implies upside of about 39.8%.

Scinai Immunotherapeutics (NASDAQ:SCNI) ended the October 9, 2026 session at USD 1.18, a decline of USD 0.03 or 2.48%. The published 52-week range runs from USD 1.12 to USD 15.80, which places the closing price about 5% above the low and far below the …

Veea (NASDAQ:VEEA) develops an edge computing and artificial intelligence platform, including the VeeaHub and VeeaONE products, and became public through a SPAC merger. Shares rose 47.29%, or USD 1.83, to USD 5.70 in the October 9, 2026 session, against a 52-week range of USD …

Capricor Therapeutics (NASDAQ:CAPR) develops cell and exosome therapies, and its lead candidate, deramiocel, targets cardiomyopathy in Duchenne muscular dystrophy. Shares fell 2.25%, or USD 0.18, to USD 7.83 in the October 9, 2026 session, far below a 52-week high of USD 40.37 and above …

Scinai Immunotherapeutics (NASDAQ:SCNI) is an Israeli biopharmaceutical company, formerly BiondVax, that develops inhaled nanobody medicines, a type of small antibody fragment known as VHH, and also offers contract development and manufacturing services. Shares fell 2.48%, or USD 0.03, to USD 1.18 in the October …

Capricor Therapeutics (NASDAQ:CAPR) develops cell and exosome therapeutics, and its lead candidate deramiocel targets cardiomyopathy linked to Duchenne muscular dystrophy. The shares appear on two published market screens at once. One covers names with high short interest positions, and the other covers companies with …

LENZ Therapeutics (NASDAQ:LENZ) is an ophthalmology company with an eye drop aimed at presbyopia, the age-related loss of near vision that affects most adults in middle age. The shares closed at USD 3.65, only USD 0.19 above the 52-week low of USD 3.46. Trading …